A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicityMarkus Borner, A. Roth, J. Bernhard et al.|Annals of Oncology|2005Cited by 103
Patient-reported endocrine symptoms, sexual functioning, and quality of life (QoL) in the IBCSG TEXT and SOFT trials: Adjuvant treatment with exemestane (E) plus ovarian function suppression (OFS) versus tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC).J. Bernhard, Fabio Puglisi, Lorenzo Pavesi et al.|Journal of Clinical Oncology|2014Cited by 14
SAKK 24/09: Safety and tolerability of bevacizumab plus paclitaxel versus bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer—A multicenter, randomized phase III trial.Christoph Rochlitz, Ralph C. Winterhalder, Roger von Moos et al.|Journal of Clinical Oncology|2014Cited by 14
The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer ResearchMarkus Borner, A Roth, J. Bernhard et al.|Journal of Clinical Oncology|2004Cited by 9
The impact of the irinotecan (IRI) schedule on quality of life in combination with capecitabine (CAP) in first-line treatment of metastatic colorectal cancer (MCC): A randomized phase II trial of the Swiss Group for Clinical Cancer ResearchMarkus Borner, A. Roth, J. Bernhard et al.|Journal of Clinical Oncology|2004Cited by 0